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A B S T R A C T
Background: Epidemiologic evidence indicates common risk factors, including air pollution exposure, for re-
spiratory and cardiovascular diseases, suggesting the involvement of common altered molecular pathways.
Objectives: The goal was to ﬁnd intermediate metabolites or metabolic pathways that could be associated with
both air pollutants and health outcomes (“meeting-in-the-middle”), thus shedding light on mechanisms and
reinforcing causality.
Methods: We applied a statistical approach named ‘meet-in-the-middle’ to untargeted metabolomics in two in-
dependent case-control studies nested in cohorts on adult-onset asthma (AOA) and cardio-cerebrovascular dis-
eases (CCVD). We compared the results to identify both common and disease-speciﬁc altered metabolic path-
ways.
Results: A novel ﬁnding was a strong association of AOA with ultraﬁne particles (UFP; odds ratio 1.80 [1.26,
2.55] per increase by 5000 particles/cm3). Further, we have identiﬁed several metabolic pathways that poten-
tially mediate the eﬀect of air pollution on health outcomes. Among those, perturbation of Linoleate metabolism
pathway was associated with air pollution exposure, AOA and CCVD.
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Conclusions: Our results suggest common pathway perturbations may occur as a consequence of chronic ex-
posure to air pollution leading to increased risk for both AOA and CCVD.
1. Introduction
Asthmatics often suﬀer from comorbidities including cardiovascular
diseases. Comorbidity inﬂuences the disease prognosis and control.
Refractory asthma is more likely to manifest with cardiovascular co-
morbidity than controlled asthma (Hekking et al., 2018). Asthma and
cardiovascular disease share common risk factors such as smoking,
obesity, aging and air pollution exposure, consistent with common
molecular pathways altered in the etiology of diseases.
Short-term eﬀects of air pollution exposure on asthma exacerbation
have long been established in adults and in children (Peel et al., 2005;
Schwartz et al., 1993; Sunyer et al., 1997). The role of air pollution in
asthma onset is less conclusive, particularly in adults (Anderson et al.,
2013; Jacquemin et al., 2012). Only a few studies used individually
assigned exposure estimates to study the eﬀects of ambient air pollution
on adult-onset asthma. The largest study sample was based on over
600,000 subjects, including 27,000 asthmatics, and demonstrated an
association of PM10 exposure – derived from a pan-European land use
regression model – with asthma prevalence (Cai et al., 2017). The
‘European Study of Cohorts for Air Pollution Eﬀects’ (ESCAPE) reported
a positive but not statistically signiﬁcant association with asthma in-
cidence in adults for all air pollution metrics (NO2, NO, PM10, PM2.5,
traﬃc load; traﬃc intensity) except PMcoarse (Jacquemin et al., 2015).
In the Swiss SAPALDIA cohort, long term improvement in air pollution
levels was associated with an attenuated age-related lung function de-
cline (Downs et al., 2007), with a decreased prevalence of respiratory
symptoms including wheezing and breathlessness (Schindler et al.,
2009), and with a decreased onset of asthma in adults (Kunzli et al.,
2009).
In addition, a growing number of epidemiological studies showed
that air pollution is associated with coronary artery disease (McGuinn
et al., 2016; Wolf et al., 2015), cardiovascular diseases (Brook et al.,
2010; Franklin et al., 2015), and cerebrovascular diseases (Stafoggia
et al., 2014) including ischemic stroke (Chung et al., 2017; Cox Jr,
2017). A recent meta-analysis within ESCAPE showed that increases in
PM2.5 and PM10 were associated with risks of fatal and total coronary
events, respectively (Cesaroni et al., 2014), and increased risk for cer-
ebrovascular diseases was reported for higher exposure to PM2.5 and
NO2(Stafoggia et al., 2014).
Ultraﬁne particles (UFP) exposure has been less studied than ex-
posure to larger particles, and no regulatory agencies have established
guidelines for UFP so far. Compared to larger particulate matter, UFP
have distinctive characteristics that may lead to higher toxicity: their
extremely small size allows them to reach deeper into the tissues and
evade clearance, and higher surface-to-mass ratio facilitates adhesion of
larger amounts of hazardous materials. Whether this indeed translates
into a higher risk of respiratory or cardiovascular diseases in humans
remains to be ascertained (Herbert and Kumar, 2017).
The biological mechanisms explaining the eﬀects of air pollution on
asthma and its phenotypes and cardio- and cerebrovascular disease
(CCVD) are still poorly understood. The best studied putative biological
mechanism is oxidative stress caused by air pollutants, followed by
pulmonary and systemic inﬂammation (Guarnieri and Balmes, 2014;
Herbert and Kumar, 2017; Newby et al., 2015; Uzoigwe et al., 2013).
Previous studies investigating the association between long-term ex-
posure to air pollution and various inﬂammatory blood biomarkers
reported inconsistent results, concerning speciﬁc cytokines and pro- or
anti-inﬂammatory eﬀects (Chuang et al., 2011; Fiorito et al., 2018;
Mostafavi et al., 2015).
Large-scale proﬁling of small molecules in biological samples has
become available recently, opening the door to the agnostic inter-
rogation of disease processes at the molecular level in epidemiological
settings. The metabolome reﬂects endogenous processes as well as the
inﬂuences from environment and behaviors, and therefore metabo-
lomics provides a unique opportunity to link genome, exposome, and
disease. Metabolomics has been increasingly applied to investigate
asthma and major adverse cardiovascular events (Kelly et al., 2017;
Kordalewska and Markuszewski, 2015; Shah et al., 2012; Wurtz et al.,
2015). However, few studies conducted an untargeted search for blood
biomarkers of air pollution exposure (Vlaanderen et al., 2017) or
asthma in adults, and none investigated the link between CCVD, asthma
and air pollution.
This study was conducted in the framework of EXPOsOMICS, an EU-
funded project to investigate the air- and water-borne exposome (Vineis
et al., 2017). One of the research questions EXPOsOMICS addresses is
the applicability of the ‘meet-in-the-middle (MITM)’ concept, i.e. in-
termediate biomarkers as evidence of causality (Vineis et al., 2013). We
have applied the MITM approach within two independent case-control
studies nested in cohorts: one on adult-onset asthma (AOA) within the
SAPALDIA cohort, the other on CCVD within EPIC Italy cohort, and we
compared the results to identify both common and disease-speciﬁc al-
tered metabolic pathways.
2. Methods
2.1. Study population
2.1.1. Asthma in SAPALDIA
Adult-onset asthma (AOA) metabolomics was studied in a nested
case-control study from the Swiss Cohort Study on Air Pollution and
Lung and Heart Diseases in Adults (SAPALDIA). A total of 9651 adults
were recruited in eight cities representing diﬀerent geographical and
meteorological environments in Switzerland in 1991 (SAPALDIA1);
8047 and 6088 of them participated in the ﬁrst follow-up in 2001–3
(SAPALDIA2) and in the second follow-up in 2010–11 (SAPALDIA3),
respectively. The study protocol was described in detail previously
(Ackermann-Liebrich et al., 2005; Martin et al., 1997). The present
study examined blood samples from SAPALDIA3. A detailed description
of the population cohort and of the study protocol was described in
detail previously (Ackermann-Liebrich et al., 2005; Martin et al., 1997).
Brieﬂy, asthma cases were selected among the self-reported diagnosis of
asthma occurred later than 16 years of age (n= 141) (Siroux et al.,
2014) and with archived blood sample available. Controls were ran-
domly sampled among the participants who never reported the fol-
lowing since SAPALDIA1: self-reported asthma; physician-diagnosed
asthma; asthma attack in the last 12months; current asthma medica-
tion; wheezing without cold in the last 12 months; three or more
asthma-related symptoms in the last 12 months (symptoms considered:
breathless while wheezing; woken up with a feeling of chest tightness;
attack of shortness of breath after exercise; attack of shortness of breath
while at rest; woken by attack of shortness of breath) (Jacquemin et al.,
2015) All cases and controls had not smoked for at least 10 years before
blood was drawn. Study participants were non-fasted at the time of
blood collection and bench time was< 2 h for all but ten cases and ﬁve
controls. Subjects' characteristics are summarized in Table 1.
2.1.2. Cardio-cerebrovascular diseases in EPIC Italy
Study participants were part of the Italian component (Turin and
Varese centers) of the EPICOR study (Bendinelli et al., 2011), which is
the cardiovascular section of the European Prospective Investigation
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into Cancer and Nutrition (EPIC) cohort (Palli et al., 2003). We de-
signed a case-control study nested in the cohort including 386 samples
(193 matched case-control pairs), using the incident density sampling
method (Richardson, 2004). Criteria for cases and controls selection
and matching, and outcome classiﬁcation and relevant covariates ac-
quisition were described previously (Fiorito et al., 2018) and sum-
marized in Supplementary material. Cases and controls were never
smokers or former smokers for at least one year. All subjects were
fasting at the time of blood collection and bench time was always lower
than 2 h for cases and controls. Table 2 summarizes the subjects'
characteristics.
This study complies with the Declaration of Helsinki principles, and
conforms to ethical requirements. All volunteers signed an informed
consent form at enrolment. The study protocol of SAPALDIA was ap-
proved by the Swiss Academy of Medical Sciences and the regional
committees for each study center and the one of EPIC by the Ethics
Committees at the International Agency for Research on Cancer (Lyon,
France) and at the Human Genetics Foundation (now IIGM, Turin, Italy)
for EPIC.
2.2. Metabolome analyses
Serum samples were analyzed with a UHPLC-QTOF-MS system
(Agilent Technologies, Palo Alto, CA, USA) in randomized order as a
single batch within study. The total number of molecular features was
11,909 and 5290 for SAPALDIA and EPIC Italy respectively. A detailed
description of laboratory and preprocessing procedures can be found in
Supplementary material. The features with non-missing values for at
least 60% of the total sample were retained. The ﬁnal data set contained
7089 and 2790 features for SAPALDIA and EPIC Italy respectively
(1452 were in common). In EPIC Italy, additional missing values were
imputed using the procedure implemented in the R package
imputeLCMD.
2.3. Air pollution exposure estimates
In SAPALDIA, annual mean exposure to PM2.5 in 2010 (SAPALDIA3
survey) of study participants was estimated by using PolluMap, a na-
tional air pollution dispersion model for Switzerland (FOEN, 2013).
Lagged estimates up to 7 years before SAPALDIA3 were obtained by
interpolation from Meteotest (FOEN, 2014). Biennial mean exposure to
UFP was estimated based on multi-area land use regression (LUR)
models derived from SAPALDIA speciﬁc-measurement campaigns con-
ducted in 2011/2012 and covering 4 out of 8 SAPALDIA study areas
(Eeftens et al., 2016). In EPIC Italy, PM2.5 exposure was estimated by a
newly developed European LUR model derived from measurements in
2010 (de Hoogh et al., 2016). UFP exposure in Turin was estimated by a
local LUR model derived from measurements in 2014/2015 (van Nunen
et al., 2017). Both SAPALDIA and EPIC Italy used the NO2 exposure
estimates provided by the aforementioned European LUR model (de
Hoogh et al., 2016). In addition to particle number concentration
(PNC), lung deposited surface area (LDSA) was used as UFP metric in
SAPALDIA. As we relied on LUR models developed to cover limited
areas, UFP estimates were available for a subset of samples, 75 AOA
cases and 115 controls, and 71 CCVD cases and 73 controls. Each
subject was assigned air pollution exposure estimates by geocoding the
residential address. In the case of SAPALDIA this was the address at the
time point of the SAPALDIA 3 survey. In the case of EPIC Italy this was
the address at the time of blood sample collection.
Table 1
SAPALDIA sample characteristics – adult-onset asthma.
AOA cases Controls AOA casesa Controlsa
N 139 196 73 115
Age [year] 59.4 (19.4) 57.1 (15.8) 60.3 (19.1) 54.8 (15.5)
Female 87 (63%) 101 (52%) 47 (64%) 62 (54%)
BMI [kg/m2] 25.7 (6.4) 24.4 (4.8) 27.0 (6.8) 24.7 (4.8)
Smokingb
Former 54 (39%) 62 (32%) 34 (47%) 37 (32%)
Never 85 (61%) 134 (68%) 39 (53%) 78 (68%)
Education levelc
Low 3 (2%) 2 (1%) 1 (1%) 2 (2%)
Middle 86 (62%) 121 (62%) 46 (63%) 72 (63%)
High 50 (36%) 73 (37%) 26 (36%) 41 (36%)
Fasting time [h] 2.7 (1.2) 2.8 (1.7) 2.9 (1.8) 2.7 (1.8)
Bench time [min] 80.0 (34.5) 80.0 (28.2) 80.0 (30.0) 80.0 (28.0)
PM2.5d [μg/m3]
t= 1 14.6 (1.9) 14.3 (1.7) 15.4 (1.5) 14.7 (2.0)
t= 2 14.7 (2.2) 14.4 (1.8) 15.7 (2.3) 14.8 (2.4)
t= 3 14.6 (2.8) 14.3 (2.2) 16.0 (2.3) 14.7 (2.4)
t= 4 16.0 (2.8) 15.6 (2.2) 16.7 (1.7) 16.2 (1.9)
t= 5 17.3 (2.3) 17.1 (2.1) 17.8 (1.8) 17.4 (1.9)
t= 6 16.5 (2.4) 16.0 (2.2) 17.2 (1.8) 16.4 (2.3)
t= 7 16.8 (3.4) 16.2 (3.0) 17.6 (3.2) 16.8 (3.2)
PNC [particles/cm3] – – 13,418 (6376) 9660 (7970)
LDSA [μm2/cm3] – – 33.9 (16.1) 27.1 (16.3)
NO2 [μg/m3] 25.0 (14.3) 21.6 (10.9) 29.3 (11.9) 23.7 (15.0)
Data are presented as count (%) or median (interquartile range). PM2.5: annual
mean estimates derived from the PolluMap in 2010; PNC and LDSA: biennial
mean estimates derived from a SAPALDIA multi-area LUR in 2011/2012; NO2:
annual mean estimates derived from a European LUR in 2010.
a Data set used for UFP MWASs, number of observation smaller due to lim-
ited availability of UFP estimates.
b Former smokers had not smoked for at least 10 years before blood was
drawn.
c Education level low: primary school; middle: secondary/middle school or
apprenticeship; high: college or university.
d 365 days average t− 1 years before the examination. Table 2
EPIC Italy sample characteristics – cardio-cerebrovascular diseases.
CCVD cases Controls CCVD casesa Controlsa
N 166 155 71 73
Center
Turin 71 (43%) 73 (47%) 71 (100%) 73 (100%)
Varese 95 (57%) 82 (53%) – –
Age [years] 56.16
(9.56)
55.55 (9.44) 58.19 (8.94) 56.95 (9.90)
Female 107 (64%) 95 (61%) 12 (17%) 13 (18%)
BMI [kg/m2] 26.34
(4.91)
26.09 (4.91) 26.34 (3.98) 26.03 (4.01)
Smokingb
Former 52 (31%) 54 (35%) 38 (53%) 38 (52%)
Never 114 (69%) 101 (65%) 33 (47%) 35 (48%)
Education levelc
Low 103 (69%) 84 (56%) 32 (45%) 22 (30%)
Middle 48 (32%) 44 (29%) 29 (41%) 31 (43%)
High 12 (8%) 22 (15%) 10 (14%) 20 (27%)
PM2.5 [μg/m3] 21.27
(2.19)
21.27 (2.16)
PNC [particles/
cm3]
14,483
(2335)
14,227 (2497)
NO2 [μg/m3] 50.30
(14.95)
49.62
(16.48)
Data are presented as count (%) or median (interquartile range). PM2.5: annual
mean estimates derived a European LUR in 2010; PNC: annual mean estimates
derived from a local LUR in 2014/2015; NO2: annual mean estimates derived
from a European LUR in 2010.
a Data set used for UFP MWASs, number of observation smaller due to lim-
ited availability of UFP estimates.
b Former smokers had not smoked for at least 1 year before blood was drawn.
c Education level: low (primary school or none), middle (vocational or an-
other secondary school), and high (university or vocational postsecondary
school).
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2.4. Statistical analyses
2.4.1. Association of air pollution exposure with AOA
We assessed the eﬀect of air pollution exposure on AOA by ﬁtting
logistic regression models. AOA was regressed, with non-asthmatics as
the reference, on air pollution exposure after adjustment for age, sex,
education level, body mass index (BMI), and study area as random ef-
fect. For PM2.5, the main predictors were two polynomial lag terms
deﬁned as u0= ∑t=17PM2.5(t) and = ∑ ∙=u t PM (t)t1 1
7
2.5 , where PM2.5(t)
is average exposure to PM2.5 of 365 days t− 1 years before SAPALDIA3
examination. For UFP and NO2, the main predictors were biennial and
annual mean estimates respectively. The association was also assessed
in the entire SAPALDIA subjects (N=3011; 272 AOA cases).
2.4.2. Association of air pollution exposure with CCVD
The association of exposure to air pollution with CCVD was assessed
in the nested case-control study by logistic regression models adjusting
for age at recruitment, center of recruitment, sex, BMI, smoking status,
and education level (see Supplementary material for details). In addi-
tion, we conducted Cox proportional hazard regression to assess the
association between air pollution exposure and the risk of future CCVD
among all EPIC subjects (Turin and Varese centers; N=18,982; 948
Fig. 1. Search for the MITM pathways.
*Adjusted for the corresponding air pollutant; ** by excluding the pathways not enriched in the other cohort.
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CCVD events).
In both studies, odds ratios (OR), hazard ratios (HR), and 95%
conﬁdence intervals (CI) refer to an increase of 5 μg/m3 PM2.5,
5000 particles/cm3 PNC, 10 μm2/cm3 LDSA, and 10 μg/m3 NO2.
2.4.3. Metabolome-wide association study (MWAS) on AOA
We conducted logistic regression analyses of AOA on each of the
7089 features after adjustment for age, sex, study area, bench time,
fasting time, sine and cosine functions of venipuncture time with per-
iods of 24 and 12 h, and their multiplicative interaction terms with
fasting time. We did not adjust for smoking because all subjects were
non-smokers since 10 years. Feature intensity, age, bench time, and
fasting time were scaled to have mean equal 0 and standard deviation
equal 1. We applied the Firth's bias-reduction method (Firth, 1993;
Perry, 2017) to obtain less biased estimates and the Benjamini-Hoch-
berg method to correct for multiple testing (Benjamini and Hochberg,
1995).
2.4.4. MWAS on CCVD
For each of the 2790 features, we tested for their association with
incident CCVD by logistic regression models adjusting for age at re-
cruitment, center of recruitment, sex, BMI, smoking status, and edu-
cation level.
2.4.5. MWAS on air pollution
In SAPALDIA and EPIC Italy separately, each feature was regressed
on PM2.5, UFP, or NO2 after adjustment for the same covariates as in
AOA MWAS and in CCVD MWAS, respectively. In SAPALDIA, a binary
indicator for perfect geocoding quality was additionally included as a
potential modiﬁer of the eﬀect of air pollution exposure on the meta-
bolite level. Geocoding was declared perfect if the matching was pos-
sible at the level of residential address. As in the association of air
pollution with AOA, ﬁrst and second order polynomial lag terms were
used for PM2.5 while biennial and annual mean exposures were used for
UFP and NO2, respectively. In EPIC Italy, annual average exposure was
used as the proxy for long-term exposure for each pollutant.
2.4.6. Link and variance functions
In EPIC Italy, feature intensities were Box-Cox transformed before
regression (Han and Kronmal, 2004). In SAPALDIA, the best link and
variance were sought for each feature and semi-partial pseudo-R2 was
computed as a measure of eﬀect size (see Supplementary material for
details).
2.5. Meet-in-the-middle (MITM) approach
2.5.1. Search for MITM features
We examined if any of the features associated with air pollution
overlapped with the features associated with AOA or CCVD as an at-
tempt to search for MITM features. As no single feature showed meta-
bolome-wide signiﬁcant association with AOA or CCVD, we found no
single MITM features. Instead, we searched for MITM pathways as de-
scribed below. The history of our analyses in this study is summarized
as ﬂowcharts in Supplementary materials (Fig. S1: MITM features;
Fig. 1: MITM pathways).
2.5.2. Functional annotation and pathway enrichment tests using
Mummichog
Mummichog is an algorithm developed to predict functional activ-
ities of metabolites (Li et al., 2013). Taking untargeted MWAS results as
input, Mummichog searches for chemical identities by matching the
measured mass (m/z) of the features to a reference metabolic model,
integrated from KEGG (Kanehisa et al., 2006), UCSD BiGG (Duarte
et al., 2007), and Edinburgh human metabolic network (Ma et al.,
2007). Based on this putative annotation, it conducts pathway enrich-
ment tests using Fisher's exact test. The statistical signiﬁcance of
pathway enrichment is estimated by permutation, where the features
are randomly selected and mapped to each of the possible annotations
to produce null distribution. We customized the types of ions that
Mummichog searches for chemical identities, to match with the
UHPLC-QTOF-MS method used. Cut-oﬀ p-value was chosen to have a
reasonable number of signiﬁcant features to ensure for the algorithm to
conduct pathway enrichment analysis. We ﬁrst used the 10th percentile
of the p-values from each MWAS result as the cut-oﬀ and then the 5th
percentile as a sensitivity analysis (Table S1).
2.5.3. Search for MITM pathways
Pathways found enriched (empirical p-value < 0.05) from
Mummichog were listed. The pathways with overlap size – the number
of features that contributed to the enrichment – smaller than 4 were
ignored. This is an attempt to reduce the false positive ﬁndings as
Mummichog annotates features only by matching m/z and hence mat-
ches are subject to error. The pathways that were not enriched for the
same air pollution metric in both SAPALDIA and EPIC Italy were ex-
cluded. If the pathway enriched for air pollution metric was also en-
riched for AOA or CCVD after adjustment for the same metric, they
were declared as “MITM” pathways (Figs. S3–S5). The MITM pathways
were evaluated by conﬁrmation of the putative annotation which
Mummichog used to compute pathway enrichment (see Supplementary
material for details).
3. Results
3.1. Exposure to UFP is associated with AOA
From logistic regression of AOA (n=73) with non-asthmatics as the
reference group (n= 115), we found a strong association of UFP ex-
posure with AOA (Table 3). The odds ratios were 1.80 [95% CI 1.26,
2.55] for an increase in particle number concentration (PNC) by
5000 particles/cm3, and 1.73 [95% CI 1.27, 2.36] for an increase in
lung deposited surface area (LDSA) by 10 μm2/cm3. On the contrary,
PM2.5 and NO2 did not show a signiﬁcant association with AOA. The
estimated risk for AOA due to UFP exposure is still signiﬁcant after the
inclusion of the other pollutants in the regression model, supporting the
independence of the eﬀect, although ORs were lower when estimated in
the whole cohort (Table S2).
3.2. Weak but consistent association of air pollution with CCVD
We have observed a positive association of exposure to PM2.5, PNC,
and NO2 with the risk of CCVD (OR=1.34 [95% CI 0.72, 2.52] for
10 μg/m3 increase in PM2.5; OR=1.09 [95% CI 0.60, 2.00] for
5000 particles/cm3 increase in PNC; OR=1.03 [95% CI 0.89, 1.18] for
μg/cm3 increase in NO2), though the associations did not reach statis-
tical signiﬁcance (Table 3). However, when we expanded the analyses
to the whole EPIC Turin-Varese subjects (N=18,982; 948 CCVD
events), the associations became stronger and signiﬁcant (HR=1.29
[95% CI 1.08, 1.55] for 10 μg/m3 increase in PM2.5; HR=1.16 [95% CI
0.97, 1.39] for 5000 particles/cm3 increase in PNC (Turin subjects;
N= 8753); HR=1.12 [95% CI 0.99, 1.27] for μg/cm3 increase in
NO2).
3.3. MWAS: no single metabolites are associated with both air pollution and
AOA or CCVD
None of the 7089 features in SAPALDIA or 2790 features in EPIC
Italy showed a signiﬁcant association with AOA or CCVD after multiple
testing corrections, respectively (Fig. S1). The air pollution MWAS in
SAPALDIA showed 237, three, six and one features signiﬁcantly asso-
ciated with PM2.5, PNC, LDSA, and NO2, respectively (Fig. 2). One of
the three PNC associated features coincided with the LDSA associated
features. Five out of the eight UFP associated features were not
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associated with any other air pollutant. The only NO2 associated feature
was also associated with PM2.5 (Fig. S2). In EPIC Italy, no single feature
showed a signiﬁcant association with air pollution exposure, nor with
CCVD after multiple testing corrections (Fig. 3). The top 100 signals
from each of the air pollution MWASs in both cohorts are summarized
in Supplementary material with putative annotation.
3.4. Several metabolic pathways are commonly associated with air pollution
in both cohorts
Various pathways were associated with air pollution varying with
the air pollutant and the cohort examined (Fig. 1, Tables S3–S9). The
pathways that were enriched for the same air pollutant in both cohorts
are summarized in Table 4 and Figs. S3–S5: Linoleate metabolism and
Fatty acid activation were enriched for PM2.5; Linoleate metabolism,
glycerophospholipid metabolism, and glycosphingolipid metabolism for
UFP; carnitine shuttle and pyrimidine metabolism for NO2. No overlap
was found looking at the list of features that contributed to the en-
richment in the two studies (Table S10). We then repeated the same
enrichment analysis using the 5th percentile p-value as the cut-oﬀ, as a
sensitivity analysis. Linoleate metabolism and glycerophospholipid
metabolism, associated to UFP, were conﬁrmed in both cohorts. All the
pathways associated to NO2, carnitine shuttle and pyrimidine metabo-
lism, were also conﬁrmed.
3.5. Pathways enrichment and MITM analysis for AOA and CCVD
We found various altered metabolic pathways associated with AOA
and CCVD (Fig. 1, Tables 5 and 6). The majority of the enriched
pathways did not overlap between AOA and CCVD. Pathways asso-
ciated with AOA and CCVD, respectively, after adjustment for single air
pollution metrics to identify MITM pathways are presented in Tables
S11–17.
3.6. Linoleate metabolism is a common MITM pathway linking air pollution
to AOA and CCVD
Linoleate metabolism was enriched for PM2.5 and UFP in both co-
horts and for AOA after adjustment for PM2.5 or UFP (Tables S11–S13)
as well as for CCVD after adjustment for PM2.5 (Table S15). Therefore,
we considered Linoleate metabolism as MITM linking PM2.5 and UFP to
AOA and PM2.5 to CCVD. Similarly, we considered glycerophospholipid
metabolism as MITM linking UFP to AOA (Table S13); fatty acid acti-
vation, glycosphingolipid metabolism, and carnitine shuttle as MITM
linking PM2.5, UFP, or NO2 to CCVD, respectively (Tables S15–S17).
Linoleate metabolism and glycerophospholipid metabolism were
conﬁrmed as MITM pathways linking UFP to AOA after the sensitivity
analysis (5th percentile of p-values as the cut-oﬀ), as well as glyco-
sphingolipid metabolism linking UFP to CCVD, and carnitine shuttle
linking NO2 to CCVD.
3.7. Conﬁrmed annotation of metabolites in MITM pathways
A total of 108 features mapping to the aforementioned MITM
pathways were selected for conﬁrmation of the putative annotation.
Table 7 summarizes all the features whose annotation was conﬁrmed
using chemical standards and fragmentation spectra. Linoleate was
conﬁrmed in both cohorts with conﬁdence level 1 according to the
classiﬁcation of the Chemical Analysis Working Group (CAWG)
(Sumner et al., 2007). In SAPALDIA, linoleate was considered as a
signal for the AOA MWAS further adjusted for UFP and contributed to
the enrichment of linoleate metabolism and glycerophospholipid me-
tabolism. In EPIC Italy, linoleate was considered as a signal for the
PM2.5 MWAS and contributed to the enrichment of linoleate metabo-
lism. Also conﬁrmed were octanoic acid, sphingosine, and L-carnitine,
contributing in EPIC Italy to the enrichment of fatty acid activation for
PM2.5, glycosphingolipid metabolism for UFP, and carnitine shuttle for
CCVD adjusted for NO2, respectively. Five additional features were
conﬁrmed for their chemical classes with conﬁdence level 3 for the
CAWG (Sumner et al., 2007).
3.8. Additional sensitivity analyses
For consistency between the two studies, we performed further
sensitivity analyses on AOA. Additional adjustment for education level
resulted in a non-relevant change of the results, while adjustment for
BMI slightly changed the results (Table S18). In the pathway enrich-
ment analyses, glycerophospholipid metabolism remained as MITM
linking UFP to AOA after adjustment for BMI or for education level.
Linoleate metabolism remained as MITM linking UFP to AOA after
adjustment for education level but not after adjustment for BMI.
4. Discussion
In short-term studies, UFP exposure has been reported to have
cardio-respiratory eﬀects that were stronger than for larger particles.
Peters et al. reported that UFP exposure had a stronger eﬀect on peak
expiratory ﬂow than larger particles (Peters et al., 1997). Exposure to
UFP but not to larger particles was associated with asthma exacerba-
tions in children (Evans et al., 2014). However, a recent in vitro study
showed that coarse particles might have stronger eﬀects on airway
epithelium, possibly due to the higher iron content in coarse particles
(Kumar et al., 2015). Studies investigating the long-term cardio-re-
spiratory eﬀects of UFP exposure remain very limited. In the California
Teachers Study cohort, UFP exposure derived from a chemical transport
model was associated with all-cause and ischemic heart disease mor-
tality (Ostro et al., 2015). In the SAPALDIA cohort, UFP exposure was
associated with carotid-intima media thickness, a marker of subclinical
Table 3
Association of air pollution with AOA and CCVD.
Air pollution
metric
AOA CCVD
ORa [95%
CI]
ORb [95%
CI]
ORc [95%
CI]
HRd [95% CI]
PM2.5e 1.05 [0.57,
1.95]
1.00 [0.65,
1.56]
1.34 [0.72,
2.52]
1.29 [1.08,
1.55]
PNCf 1.80 [1.26,
2.55]
1.39 [1.03,
1.87]
1.09 [0.60,
2.00]
1.16 [0.97,
1.39]
LDSAg 1.73 [1.27,
2.36]
1.36 [1.04,
1.79]
– –
NO2h 1.12 [0.81,
1.55]
1.16 [0.94,
1.43]
1.03 [0.89,
1.18]
1.12 [0.99,
1.27]
Note: Odds ratios are reported for all cross-sectional analyses (meet-in-the-
middle/metabolome subsample) while hazard ratio is reported for the long-
itudinal analysis on larger CCVD samples; sample size is smaller for UFP than
other pollutants because the LUR models were derived only for 4 out of 8 study
areas in SAPALDIA and for Turin but not for Varese in EPIC Italy.
a Odds ratio adjusted for age, sex, education level, BMI, and study area as
random eﬀect (N= 335 for PM2.5 and NO2; N=188 for UFP).
b Odds ratio adjusted for age, sex, education level, BMI, and study area as
random eﬀect (N= 3011 for PM2.5 and NO2; N=1555 for UFP).
c Odds ratio adjusted for age, center of recruitment, sex, BMI, smoking status,
and educational level (N=321 for PM2.5 and NO2; N=144 for UFP).
d Hazard ratio adjusted for age, center of recruitment, sex, BMI, smoking
status, and educational level (N=18,982 for PM2.5 and NO2; N=8753 for
UFP).
e Per 5 μg/m3 increase in biennial (SAPALDIA) or annual (EPIC Italy) mean
PM2.5.
f Per increase by 5000 particles/cm3 in biennial (SAPALDIA) or annual (EPIC
Italy) mean PNC.
g Per increase by 10 μm2/cm3 in biennial mean LDSA.
h Per increase by 10 μg/m3 in annual mean NO2.
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atherosclerosis (Aguilera et al., 2016). UFP exposure derived from a
city-speciﬁc LUR model in Toronto linked to health registry data of 1.1
million adult city residents found no positive association of UFP ex-
posure with respiratory disease incidence including AOA (Weichenthal
et al., 2017). This is in contrast to our ﬁndings, which are based on
individual reports of asthma and which provide evidence of UFP eﬀects
being stronger than, and independent of, those of larger particles.
Traﬃc-related pollutants contribute mainly to the ﬁne or ultraﬁne
particles, while specks of dust of geological origin including metals link
to the coarse particles (Kelly and Fussell, 2012; Yamada et al., 2005).
Particulates of various sizes may have diﬀerent toxicity dependent on
their composition (Kumar et al., 2015; Schwarze et al., 2007).
4.1. Meet-in-the-middle (MITM) approach
We applied the ‘meet-in-the-middle (MITM)’ approach, which helps
in developing a causal hypothesis and improve biological under-
standing for air pollution-cardio-respiratory health associations,
making use of high-resolution metabolomic data. In the MITM ap-
proach, one searches for intermediate biomarkers that are associated
with both the exposure and the outcome (Vineis et al., 2013). Ideally,
this applies to longitudinal studies where the exposure precedes the
biomarker measurement, and the biomarker measurement precedes the
outcome, e.g. incidence of cardiovascular events, as we did for CCVD in
EPIC Italy. It is much less straightforward to deﬁne incident cases for
asthma than for CCVD. Asthma is a complex chronic disease phenotype
Fig. 2. Volcano plots of MWAS results in SAPALDIA.
Note the asymmetric distribution of points in air pollution MWASs due to the positive nature of semi-partial pseudo-R2 used as a measure of eﬀect size. Linoleate (m/
z=281.2464; RT=7.283) whose annotation was conﬁrmed with conﬁdence level 1 is highlighted in red; Metabolome-wide signals after Benjamini-Hochberg
correction in black. Dotted line depicts Benjamini-Hochberg adjusted p= 0.05.
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that develops over a long period of time, can go unnoticed for years if
not for decades, and can also disappear as well as resurface. This dif-
ﬁculty inherent to asthma research is complicating the assessment of
causality to identiﬁed risks such as air pollution. Realizing this diﬃ-
culty, we pursued the MITM approach for asthma even though our
study is by design cross-sectional. For all these reasons, we restricted
the outcome to adult (after the 16 years of age) onset of asthma which is
less susceptible to reverse causation bias and exposure misclassiﬁcation.
4.2. MWAS analyses
At the level of single metabolites, we found no intermediate bio-
markers among the 7089 and 2790 features investigated in SAPALDIA
and EPIC Italy respectively, due to lacking metabolome-wide signiﬁcant
associations. Multiple testing corrections can be too stringent, given the
highly inter-correlated nature of the metabolome. The eﬀective number
of tests (ENT) computed for the SAPALDIA metabolome was 2728, in-
dicating a high degree of dependency in the data. Given this highly
correlated, high dimensional data structure, our study likely suﬀers
from low power to detect subtle diﬀerences related to chronic diseases,
Fig. 3. Volcano plots of MWAS results in
EPIC Italy.
Metabolites whose annotation was con-
ﬁrmed with conﬁdence level 1 are high-
lighted in red: Linoleate (m/z=281.2481;
RT=7.306), octanoic acid (m/
z=127.1119; RT=4.388), sphingosine
(m/z=300.2903; RT=6.019), and L-car-
nitine (m/z=162.1128; RT=0.601); me-
tabolites whose annotation was conﬁrmed
with conﬁdence level 3 are in blue: α-
Linolenic acid (m/z=279.2321;
RT=7.166), D-glucose (m/z=145.0495;
RT=0.646), linoelaidyl carnitine (m/
z=424.3428; RT=6.199), octadecenoyl
carnitine (m/z=426.3590; RT=6.337),
and stearoylcarnitine (m/z=428.373;
RT=6.479). No metabolome-wide signals
after Benjamini-Hochberg correction.
Table 4
Pathways associated to air pollution in both SAPALDIA and EPIC Italy.
Air pollutant Pathway SAPALDIA EPIC Italy
Overlap size Pathway size p-Value Overlap size Pathway size p-Value
PM2.5 Linoleate metabolismb,c 17 21 0.0007 6 20 0.0249
Fatty acid activationc 10 21 0.0054 5 15 0.0180
UFPa Linoleate metabolismb 12 21 0.0007 7 20 0.0084
Glycerophospholipid metabolismb 12 36 0.0023 13 35 0.0022
Glycosphingolipid metabolismc 8 26 0.0079 6 21 0.0367
NO2 Carnitine shuttlec 10 26 0.0063 6 19 0.0040
Pyrimidine metabolism 12 33 0.0074 8 28 0.0035
a Either PNC or LDSA in SAPALDIA and PNC in EPIC Italy.
b Also enriched for AOA after further adjustment for the corresponding air pollutant.
c Also enriched for CCVD after further adjustment for the corresponding air pollutant.
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and in particular to asthma, where distinguishing sub-phenotypes may
be essential for understanding risk and etiology of the disease (Jeong
et al., 2017; Siroux et al., 2014; Wenzel, 2012). Therefore, hetero-
geneity and misclassiﬁcation might have attenuated the associations
with biomarkers. Distinguishing further sub-phenotypes requires larger
data in future metabolome studies. Given the above, we focused on
pathway enrichment analyses.
4.3. Pathway enrichment analyses
Metabolomics, given the high dimensionality and high dependency,
beneﬁts much from multivariate systems approaches like pathway en-
richment tests. Yet, the challenge unique to metabolomics in this con-
text is annotation. Unlike other omics, annotation of the features ob-
tained from untargeted metabolomics requires laborious manual work.
The Mummichog software oﬀers an opportunity to bypass this step and
to conduct pathway enrichment tests directly from untargeted MWAS
results. Using Mummichog, we found various pathways enriched for
AOA, CCVD, and air pollution exposures. Air pollution MWASs and
pathway enrichment tests conducted in two cohorts served as each
other's validation. Although we found no single overlapping features
between the two cohorts when comparing validated pathways, lack of
such overlap does not exclude the possibility that the pathways truly
reﬂect air pollution-induced metabolic changes, involving diﬀerent
molecules. The speciﬁc molecules aﬀected in a pathway may, for ex-
ample, depend on the particle composition which can vary across dif-
ferent areas (Kelly and Fussell, 2012).
4.4. Linoleate metabolism is a common MITM pathway for AOA and CCVD
AOA and CCVD were mostly associated with diﬀerent sets of path-
ways and hence MITM pathways linking air pollution exposure to both
chronic diseases diﬀered. The two chronic diseases may involve dif-
ferent biological mechanisms and the same environmental insults may
act through diﬀerent pathways. One exception was linoleate metabo-
lism pathway, which was found not only as MITM pathway linking
PM2.5 and UFP to AOA but also linking PM2.5 to CCVD. Laboratory
analysis conﬁrmed the annotation of linoleate in both cohorts. The
feature conﬁrmed as linoleate showed a positive association with AOA,
while it did not show statistically signiﬁcant association with UFPs
exposure and did not contribute to the pathway enrichment for UFPs.
Still, the lineolate MITM-pathway ﬁnding seems biologically inter-
esting. Linoleate was reported in an in vitro experiment to regulate the
pro-inﬂammatory cytokine IL8 (Maruyama et al., 2014) and induce
smooth muscle contraction via the free fatty acid receptor 1 (FFAR1)
(Mizuta et al., 2015). Another in vitro study demonstrated that α1-
antitrypsin bound to linoleate reduced the expression and secretion of
IL1β in LPS-stimulated neutrophils, while free α1-antitrypin did not
(Aggarwal et al., 2016). In observational studies in children, eczema
was positively associated with linoleate intake (Miyake et al., 2011) and
atopy with circulating linoleate (Yen et al., 2008). A recent targeted
metabolomic study investigated 64 lipid metabolites and reported Li-
noleate metabolism and Arachidonic acid metabolism as the top path-
ways albeit not statistically signiﬁcantly associated with asthma control
(McGeachie et al., 2015). Few studies associated linoleate with CCVD,
although in general ω−6 fatty acids have long been believed to have
pro-inﬂammatory eﬀects in the cardiovascular system. An early in vitro
study suggested that linoleate may lead to atherogenesis by NFκB sig-
naling mediated vascular adhesion molecule-1 (VCAM-1) expression
(Dichtl et al., 2002).
4.5. CCVD speciﬁc MITM pathways
Glycosphingolipid metabolism was found as MITM pathway linking
exposure to UFP and CCVD and annotation of sphingosine was con-
ﬁrmed as one of the modulated metabolites in this pathway.
Sphingolipids are structural components of cell membrane but known
to play a crucial role in apoptosis, cell growth, senescence, and cell
cycle control (Yang et al., 2004). Sphingolipids in blood have been
associated with cardiovascular diseases including acute coronary syn-
drome (Pan et al., 2014) and myocardial infarction (Park et al., 2015).
A recent clinical trial reported a strong association between blood
sphingolipids and incident cardiovascular diseases (Wang et al., 2017).
Sphingolipids have also been associated with asthma (Petrache and
Berdyshev, 2016) in contrast to our ﬁndings. Perturbation of sphingo-
lipid metabolism may be more relevant for allergic or child-onset
asthma (Ono et al., 2015).
Carnitine shuttle pathway was identiﬁed as a MITM pathway
linking exposure to NO2 and CCVD. Carnitines facilitate the transport of
long-chain fatty acids from the cytosol into the mitochondria and play
an important role in fatty acid metabolism and carbohydrate utiliza-
tion. The role of L-carnitine in CCVD has been extensively described,
reporting protective eﬀects of L-carnitine administration for various
cardiovascular diseases including coronary artery disease, congestive
heart failure, and hypertension (Ferrari et al., 2004). A recent meta-
Table 5
Pathways associated to AOA unadjusted for air pollution exposure.
Pathway Overlap size Pathway size p-Value
Tryptophan metabolism 20 54 0.0009
Vitamin B6 (pyridoxine) metabolism 4 6 0.0017
Biopterin metabolism 6 13 0.0021
TCA cycle 4 8 0.0041
Hexose phosphorylation 5 12 0.0048
Fatty acid metabolism 5 14 0.0101
De novo fatty acid biosynthesis 7 22 0.0102
Drug metabolism - cytochrome P450 12 42 0.0102
Valine, leucine and isoleucine
degradation
7 23 0.0137
Urea cycle/amino group metabolism 9 32 0.0169
Fatty acid activation 6 21 0.0258
Leukotriene metabolism 13 51 0.0278
Butanoate metabolism 5 17 0.0284
Glycosphingolipid metabolism 7 26 0.0312
Lysine metabolism 6 22 0.0342
Drug metabolism - other enzymes 5 18 0.0387
Arginine and proline metabolism 6 23 0.0447
Starch and sucrose metabolism 4 14 0.0458
Pentose and glucuronate
interconversions
4 14 0.0458
Vitamin E metabolism 8 32 0.0461
Mummichog pathway enrichment test on the results from AOA MWAS adjusted
for age, sex, study area, bench time, fasting time, sine and cosine functions of
venipuncture time with periods of 24 and 12 h, and their multiplicative inter-
action terms with fasting time.
Table 6
Pathways associated to CCVD unadjusted for air pollution exposure.
Pathway Overlap size Pathway size p-Value
De novo fatty acid biosynthesis 9 14 0.0011
Hexose phosphorylation 8 12 0.0012
Phosphatidylinositol phosphate
metabolism
6 10 0.0031
Carnitine shuttle 9 19 0.0047
Starch and sucrose metabolism 6 11 0.0051
Linoleate metabolism 9 20 0.0070
Glycosphingolipid metabolism 9 21 0.0105
Glutamate metabolism 5 10 0.0139
Caﬀeine metabolism 5 11 0.0249
Fatty acid activation 6 15 0.0398
Glycolysis and gluconeogenesis 4 9 0.0479
Fructose and mannose metabolism 4 9 0.0479
Mummichog pathway enrichment test on the results from CCVD MWAS ad-
justed for age at recruitment, center of recruitment, sex, BMI, smoking status,
and education level.
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analysis of randomized controlled trials demonstrated the eﬃcacy of L-
carnitine against chronic heart failure (Song et al., 2017). In an ex-
perimental study in rats, inﬂammation accompanied with hypertension
was attenuated by L-carnitine administration (Miguel-Carrasco et al.,
2008). In this study, however, L-carnitine was associated with increased
risk of CCVD.
4.6. Strengths and limitations
Strengths of our study include its prospective nature (nested in
longitudinal cohorts), the individual assessment of exposure to air
pollution, the accurate diagnoses for the outcomes, the agnostic nature
of our metabolome-wide measurements, and the application of ‘meet-
in-the-middle’ as a novel approach helping in the causal interpretation
of the results. We focused on biological pathways that were associated
with air pollution (mostly UFP) in both studies, supporting the ro-
bustness and replicability of our ﬁndings. Limitations include the small
sample size for metabolome-wide analyses; we focused on pathways
enrichment but we were not able to identify single features associated
with both air pollution and at least one disease due to the lack of sta-
tistical power. Also, we used slightly diﬀerent statistical methods (in-
cluding the set of confounders) in the two studies, mainly due to the
nature of the outcomes and the quite diﬀerent estimation of exposure in
the two studies. For example, unlike in EPIC Italy, we did not adjust for
BMI in SAPALDIA. Air pollution exposure can increase the risk of
obesity (Eze et al., 2015; Wei et al., 2016) and obesity may have a
causal eﬀect on asthma (Wenzel, 2012), therefore adjustment for BMI
can lead to missing some signals. Given the smaller sample size and
expected subtle eﬀects, parsimony was more strongly sought in AOA
MWAS. And a previous study observed less strong association between
socioeconomic status and air pollution exposure in Switzerland than in
Italy (Temam et al., 2017). Sensitivity analysis showed that the addi-
tional adjustment did not change the results.
5. Conclusions
In summary, we successfully applied a MITM approach in un-
targeted metabolomics to produce evidence of common and disease-
speciﬁc pathway perturbations in the etiological relationship between
air pollution exposure, AOA, and CCVD. Our ﬁndings need to be con-
ﬁrmed in future targeted and untargeted studies.
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